Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Innovative medicines for the treatment of hormonally-driven cancers.
Aisling congratulates the management teams of Aragon and Seragon on their recent acquisitions by Johnson & Johnson and Genentech, respectively.
learn moreLearn More About Aragon & Seragon
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Dalvance™ for the treatment of acute bacterial skin and skin structure infections.
Aisling congratulates the management team of Durata on its recent acquisition by Actavis.
Learn More About Durata
Diagnostics to accurately identify sepsis pathogens in hours instead of days.
Learn More About T2 BiosystemsAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
TransEnterix CEO, Todd Pope, featured in TIME's "The 50 Most Influential People in Health Care of 2018"
October 18, 2018
Todd Pope, TransEnterix President and CEO, was recently named to TIME's "The 50 Most Influential People in Health Care of 2018." The list honors fifty people transforming health care, across…
READ MORE
TapImmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing
October 18, 2018
Jacksonville, FL, October 17, 2018 —TapImmune Inc. (NASDAQ: TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc. In connection with the merger, TapImmune Inc.…
READ MORE
Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
October 17, 2018
AUSTIN, Texas, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic…
READ MORE